St Gallen International Breast Cancer Congress 2019 Highlights - Adjuvant therapy in high-risk breast cancer
Learning Objectives Introduction


Watch an internationally renowned faculty discuss the changing landscape for adjuvant treatment of patients with high-risk breast cancer.

Prof. Christoph Zielinski, Prof. François-Clément Bidard and Prof. Valentina Guarneri discuss new targeted therapy for high-risk early breast cancer, the need for a differentiated approach to patient management and how current research may shape the way these patients are managed in the future.

The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer.

This ACCME-accredited touchSATELLITE SYMPOSIUM was recorded live during the 16th St. Gallen International Breast Cancer Conference in March 2019. (The live voting content is no longer active for this symposium.)

Learning objectives

After watching this touchSATELLITE SYMPOSIUM, you should be able to:

1 AMA PRA Category 1 Credits™ Date of original release: April 9, 2019 Date credits expire: April 9, 2020

Back to Education Zone


What’s on the horizon for high-risk breast cancer in the adjuvant setting?

1 AMA PRA Category 1 Credits™ Date of original release: April 9, 2019 Date credits expire: April 9, 2020

Clinical Spotlight

Breast cancer is the most commonly diagnosed, and the second leading cause of cancer-related deaths among women worldwide.1 Hormone receptor-positive (HR+) is the most common type of breast cancer, constituting 75% of all breast cancers, with this frequency increasing in pre-menopausal women.2-4 In HR+ early-stage breast cancer, adjuvant endocrine therapy (ET) has been the standard of care. However, many patients acquire resistance to ET and disease progression eventually occurs.4 In this symposium, the expert faculty address key questions such as which therapies should be considered in patients with high-risk breast cancer to address the inevitable challenges of treatment resistance and how new therapies could potentially be integrated into future treatment strategies. An interactive case presentation will be used to illustrate the differentiated approach to the management of patients with breast cancer in the adjuvant setting.


Module 1: Potential of new targeted agents in high-risk early breast cancer – are we entering a new era?

Prof. Valentina Guarneri describes new strategies that are under evaluation for high-risk early breast cancer, including CDK4/6 inhibitors and immunotherapies. She addresses the importance of baseline assessment and how dynamic risk assessment can inform treatment outcomes.

Start Module

Module 2: Panel Discussion

Prof. Christoph Zielinski leads a panel discussion on the relevance of clinical trials assessing CDK4/6 inhibitors as adjuvant therapy, how these treatments can be differentiated and the potential utility of these treatments in the future management of high-risk early breast cancer.

Start Module

Module 3: The high-risk early breast cancer patient – how can we apply a differentiated approach in the clinic?

Prof. François-Clément Bidard presents an interactive case study of a patient with early breast cancer. He considers how to tailor adjuvant treatment, the requirements for future therapies, the impact on patient fertility and the need for combination therapy.

Start Module

Director of the Vienna Cancer Center, Medical University Vienna and Vienna Hospital Association, Vienna, Austria

Christoph Zielinski is President of the Central European Cooperative Oncology Group and a member of the European Society for Medical Oncology (ESMO) where he served on the Executive Board and as Chair of the Fellowships and Awards Committee from 2014–2017. He is also a member of several other Haematology and Clinical Oncology societies. His clinical research activities cover a wide range of cancer therapies, with particular focus on clinical trials, breast and lung cancer research (including the development of concepts related to immuno-oncology and targeted drugs). Professor Zielinski is Editor in Chief of the peer-reviewed open-access Internet journal ESMO Open – Cancer Horizons and has published over 600 original papers and reviews in peer-reviewed journals and many books.

Disclosures: Advisory role for Ariad, AstraZeneca, Bristol-Myers Squibb, Fibrogen, Gilead, Imugene, Merck KGaA, Merrimack, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Servier, Shire, Tesaro. Research grant from AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer and lecture fees from Ariad, AstraZeneca, Bristol-Myers Squibb, Fibrogen, Gilead, Imugene, Merck KGaA, Merrimack, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Servier, Shire, Tesaro.

Associate Professor of Oncology Department of Surgery, Oncology and Gastroenterology, University of Padova, Istituto Oncologico Veneto IRCCS, Italy

Valentina Guarneri is the head of the Translational Research and Innovative Therapy Unit Istituto Oncologico Veneto IRCCS, Padova and the Vice-Director of the Specialty Programme in Medical Oncology. In addition to being a member of the Research Committee of the Italian Ministry, she is also a member of the ESMO Fellowship and Award Committee and the Oncology Pro-Working Group and a founder member of the Women for Oncology Italy initiative. She is on the editorial review board of several International journals and has more than 100 peer-reviewed publications. Her research interest is focused on clinical and translational research for breast cancer patients.

Disclosures: Advisory role for Eli Lilly. Research grant from Roche. Lecture fees from AstraZeneca, Eli Lilly and Novartis.

Professor of Medical Oncology, Institut Curie and Versailles Saint-Quentin-en-Yvelines University, Paris and Saint Cloud, France

François-Clément Bidard is a medical oncologist devoted to breast cancer care. In addition to clinical practice, his translational research interests include metastasis-associated biomarkers, with a focus on circulating tumour biomarkers and liquid biopsies in breast cancer and other tumour types. Professor Bidard is the Principal Investigator of several phase II and III trials investigating new therapies for breast cancer including CDK4/6 inhibitors and the clinical utility of circulating biomarkers. He is part of the Editorial Board of Oncogene and has authored more than 100 publications.

Disclosures: Advisory role for Eli Lilly and Pfizer. Research grant from Novartis and Pfizer. Lecture fees from Novartis and Pfizer